Fig. 3From: Cost-utility analysis of Palivizumab for Respiratory Syncytial Virus infection prophylaxis in preterm infants: update based on the clinical evidence in SpainProbabilistic sensitivity analysis. a Cost-effectiveness plane. b Acceptability curveBack to article page